Assessment of Circulating MicroRNAs for the Diagnosis and Disease Activity Evaluation in Patients with Ulcerative Colitis by Using the Nanostring Technology

Tools

Polytarchou, C. ORCID: 0000-0002-1948-7934, Oikonomopoulos, A., Mahurkar, S., Touroutoglou, A., Koukos, G., Hommes, D.W. and Iliopoulos, D., 2015. Assessment of Circulating MicroRNAs for the Diagnosis and Disease Activity Evaluation in Patients with Ulcerative Colitis by Using the Nanostring Technology. Inflammatory Bowel Diseases, 21 (11), pp. 2533-2539. ISSN 1078-0998

Preview

Text
PubSub3646_Polytarchou.pdf - Post-print
Download (619kB) | Preview

Official URL: http://dx.doi.org/10.1097/mib.0000000000000547

Abstract

Background: Clinical decision and patient care management in inflammatory bowel diseases is largely based on the assessment of clinical symptoms, while the biomarkers currently in use poorly reflect the actual disease activity. Therefore, the identification of novel biomarkers will serve an unmet clinical need for IBD screening and patient management. We examined the utility of circulating microRNAs for diagnosis and disease activity monitoring in ulcerative colitis (UC) patients.
Methods: Blood serum microRNAs were isolated from UC patients with active and inactive disease and healthy donors. High-throughput microRNA profiling was performed using the Nanostring technology platform. Clinical disease activity was captured by calculating the partial Mayo score. C-reactive protein (CRP) was measured in UC patients as part of their clinical monitoring. The profiles of circulating microRNAs and CRP were correlated with clinical disease indices.
Results: We have identified a signature of 12 circulating microRNAs that differentiate UC patients from control subjects. Moreover, six of these microRNAs significantly correlated with UC disease activity. Importantly, a set of four microRNAs (hsa-miR-4454, hsa-miR-223-3p, hsa-miR-23a-3p, and hsa-miR-320e) which correlated with UC disease activity, were found to have higher sensitivity and specificity values than CRP.
Conclusions: Circulating microRNAs provide a novel diagnostic and prognostic marker for UC patients. The use of an FDA approved platform could accelerate the application of microRNA screening in a GI clinical setting. When used in combination with current diagnostic and disease activity assessment modalities, microRNAs could improve both IBD screening and care management.

Item Type:

Journal article

Publication Title:

Inflammatory Bowel Diseases

Creators:

Polytarchou, C., Oikonomopoulos, A., Mahurkar, S., Touroutoglou, A., Koukos, G., Hommes, D.W. and Iliopoulos, D.

Publisher:

Lippincott Williams & Wilkins

Date:

2015

Volume:

Number: